Moderate riskFDA DeviceClass II

Edwards EVOQUE tricuspid delivery system receives updated labeling for valve functionality warnings

Edwards Lifesciences has updated the labeling for its EVOQUE tricuspid delivery system to include a warning about potential loss of device functionality during valve replacement procedures. This is a labeling change to help clinicians recognize and respond to compromised system performance. No injuries have been reported.

From the FDA notice · Read the official notice ↗

What to do

  1. Review the updated labeling for the EVOQUE tricuspid delivery system (REF:9850TDS) if you use or manage this device in a clinical setting
  2. Contact Edwards Lifesciences directly with questions about the labeling update or device functionality

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EO
Sold in
Nationwide
Made for
All ages (0 months and older)

Details

Illnesses reported
None reported
Manufactured in
1 Edwards Way, Irvine, CA, United States
Classification
Class II
Recall number
Z-2172-2026

In the FDA's words

Description
Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EO Labeling update to provide warning if functionality of the valve replacement delivery system is compromised. All Lots/UDI:0690103D004EVD000V5 Distribution: Worldwide - US Nationwide distribution including in the states of AR, AZ, CA, CO, CT, DE, FL, GA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MT, NC, ND, NE, NH, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV and the countries of Saudi Arabia, Germany, United Kingdom.
Hazard
Labeling update to provide warning if functionality of the valve replacement delivery system is compromised.

More from Edwards Lifesciences

Related topics